Diplomat Pharmacy Inc (NYSE:DPLO) Shares Purchased by State of Alaska Department of Revenue

State of Alaska Department of Revenue boosted its position in Diplomat Pharmacy Inc (NYSE:DPLO) by 127.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,876 shares of the company’s stock after purchasing an additional 24,547 shares during the period. State of Alaska Department of Revenue owned approximately 0.06% of Diplomat Pharmacy worth $214,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Nomura Holdings Inc. acquired a new stake in shares of Diplomat Pharmacy during the 2nd quarter valued at $178,000. Royal Bank of Canada lifted its position in shares of Diplomat Pharmacy by 184.8% during the 2nd quarter. Royal Bank of Canada now owns 4,782 shares of the company’s stock valued at $29,000 after acquiring an additional 3,103 shares during the last quarter. Walleye Trading Advisors LLC lifted its position in shares of Diplomat Pharmacy by 180.7% during the 2nd quarter. Walleye Trading Advisors LLC now owns 32,000 shares of the company’s stock valued at $195,000 after acquiring an additional 20,600 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. acquired a new stake in shares of Diplomat Pharmacy during the 2nd quarter valued at $77,000. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Diplomat Pharmacy by 5.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 192,456 shares of the company’s stock valued at $1,172,000 after acquiring an additional 9,800 shares during the last quarter. Hedge funds and other institutional investors own 84.58% of the company’s stock.

Shares of NYSE:DPLO opened at $5.16 on Tuesday. The company’s fifty day moving average is $5.32 and its two-hundred day moving average is $5.38. The company has a quick ratio of 0.66, a current ratio of 0.99 and a debt-to-equity ratio of 1.53. Diplomat Pharmacy Inc has a 12-month low of $4.17 and a 12-month high of $21.48. The company has a market cap of $391.29 million, a P/E ratio of 25.80 and a beta of 0.99.

Diplomat Pharmacy (NYSE:DPLO) last announced its earnings results on Friday, August 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Diplomat Pharmacy had a negative net margin of 8.93% and a negative return on equity of 4.01%. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.23 billion. During the same period last year, the firm earned ($0.05) earnings per share. Diplomat Pharmacy’s revenue for the quarter was down 9.1% compared to the same quarter last year. Equities research analysts anticipate that Diplomat Pharmacy Inc will post -0.81 earnings per share for the current year.

DPLO has been the subject of a number of recent research reports. Wells Fargo & Co increased their price objective on Diplomat Pharmacy from $5.00 to $5.50 and gave the company a “market perform” rating in a research report on Tuesday, August 13th. Zacks Investment Research upgraded Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Monday, October 14th. ValuEngine upgraded Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Barclays set a $7.00 price objective on Diplomat Pharmacy and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Deutsche Bank initiated coverage on Diplomat Pharmacy in a research report on Thursday, September 12th. They set a “sell” rating and a $4.00 price objective for the company. Three analysts have rated the stock with a sell rating, ten have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $9.43.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Read More: What is basic economics?

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.